Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 18/20 | 0.65 |
| ▸ | MAOA | P21397 | 5/20 | 0.65 |
| ▸ | MAOB | P27338 | 5/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12886008 | 1.00 | KDM1A (0.65) | KDM1AMAOAMAOB | |
| SCHEMBL23374693 | 1.00 | KDM1A (0.65) | KDM1AMAOAMAOB | |
| SCHEMBL15778147 | 0.85 | KDM1A (0.61) | KDM1AMAOAMAOB | |
| SCHEMBL25069768 | 0.84 | KDM1A (0.62) | KDM1AMAOAMAOB | |
| SCHEMBL25069673 | 0.82 | KDM1A (0.46) | KDM1AMAOAMAOB | |
| SCHEMBL25069676 | 0.82 | KDM1A (0.46) | KDM1AMAOAMAOB | |
| SCHEMBL15778201 | 0.81 | KDM1A (0.57) | KDM1AMAOAMAOB | |
| SCHEMBL15777424 | 0.81 | KDM1A (0.57) | KDM1AMAOAMAOB | |
| SCHEMBL4129699 | 0.80 | KDM1A (0.65) | KDM1AMAOAMAOB | |
| SCHEMBL4129698 | 0.80 | KDM1A (0.65) | KDM1AMAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2928457-A1 | CYCLOPROPYLAMINE DERIVATIVES USEFUL AS INHIBITORS OF HISTONE DEMETHYLASES KDM1A | Istituto Europeo di Oncologia S.r.l. (IT) | 2015-10-14 | — | — | EP | claimed |
| WO-2014086790-A1 | CYCLOPROPYLAMINE DERIVATIVES USEFUL AS INHIBITORS OF HISTONE DEMETHYLASES KDM1A | ISTITUTO EUROPEO DI ONCOLOGIA S.R.L. (IT) | 2014-06-12 | — | — | WO | claimed |
| WO-2017195216-A1 | CYCLOPROPYL-AMIDE COMPOUNDS AS DUAL LSD1/HDAC INHIBITORS | JUBILANT BIOSYS LIMITED (IN) | 2017-11-16 | — | — | WO | disclosed |
| WO-2017097865-A9 | COMBINATION OF CALORIC RESTRICTION (CR) OR IGF1/INSULIN RECEPTOR INHIBITOR WITH LSD1 INHIBITOR | ISTITUTO EUROPEO DI ONCOLOGIA (IT) | 2017-08-31 | — | — | WO | disclosed |
| WO-2017097865-A1 | COMBINATION OF CALORIC RESTRICTION (CR) OR IGF1/INSULIN RECEPTOR INHIBITOR WITH LSD1 INHIBITOR | ISTITUTO EUROPEO DI ONCOLOGIA (IT) | 2017-06-15 | — | — | WO | disclosed |
| US-9271967-B2 | 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors | Janssen Pharmaceuticals, Inc. (US) | 2016-03-01 | — | — | US | disclosed |
| EP-2928457-A1 | CYCLOPROPYLAMINE DERIVATIVES USEFUL AS INHIBITORS OF HISTONE DEMETHYLASES KDM1A | Istituto Europeo di Oncologia S.r.l. (IT) | 2015-10-14 | — | — | EP | disclosed |
| US-9108953-B2 | Quinoline derivatives as bromodomain inhibitors | GILEAD SCIENCES, INC. (US) | 2015-08-18 | — | — | US | disclosed |
| WO-2014086790-A1 | CYCLOPROPYLAMINE DERIVATIVES USEFUL AS INHIBITORS OF HISTONE DEMETHYLASES KDM1A | ISTITUTO EUROPEO DI ONCOLOGIA S.R.L. (IT) | 2014-06-12 | — | — | WO | disclosed |
| WO-2012062750-A1 | 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | Janssen Pharmaceuticals, Inc. (US) | 2012-05-18 | — | — | WO | disclosed |
| US-20070275964-A1 | CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | PFIZER, INC. | 2007-11-29 | — | — | US | disclosed |
| US-7268133-B2 | Cannabinoid receptor ligands and uses thereof | PFIZER, INC. PATENT DEPARTMENT (US) | 2007-09-11 | — | — | US | disclosed |
| US-20040214837-A1 | Cannabinoid receptor ligands and uses thereof | PFIZER INC. | 2004-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040214837-A1 | Cannabinoid receptor ligands and uses thereof | CNR1, CNR2, GPR18 | KDM1A 3392/4885MAOA 1687/4885MAOB 1390/4885 |
| US-20070275964-A1 | CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | CNR1, CNR2, GPR18 | KDM1A 3594/4885MAOA 1615/4885MAOB 1250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.